ORIC Pharmaceuticals Ownership | Who Owns ORIC Pharmaceuticals?
ORIC Pharmaceuticals Ownership Summary
ORIC Pharmaceuticals is owned by 20.47% institutional investors, 6.71% insiders, and 72.82% retail investors. Nextech invest is the largest institutional shareholder, holding 9.17% of ORIC shares. State Street® SPDR® S&P® Biotech ETF is the top mutual fund, with 2.71% of its assets in ORIC Pharmaceuticals shares.
ORIC Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | ORIC Pharmaceuticals | 20.47% | 6.71% | 72.82% |
| Sector | Healthcare Stocks | 232.01% | 10.74% | -142.75% |
| Industry | Biotech Stocks | 381.47% | 10.55% | -292.02% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Nextech invest | 7.16M | 9.17% | $85.95M |
| Ecor1 capital | 6.73M | 8.61% | $80.74M |
| Vr adviser | 6.60M | 8.44% | $79.16M |
| Viking global investors lp | 6.57M | 8.41% | $78.87M |
| Nextech invest | 5.29M | 7.49% | $42.66M |
| Blackrock | 4.83M | 7.17% | $34.15M |
| Blackrock funding, inc. /de | 5.88M | 5.94% | $48.06M |
| Alkeon capital management | 4.50M | 5.77% | $54.05M |
| Pfizer | 5.38M | 5.43% | $43.98M |
| Nea management company | 4.12M | 5.27% | $49.42M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Column group | 3.54M | 52.48% | $42.49M |
| Pfizer | 5.38M | 18.60% | $43.98M |
| Nextech invest | 7.16M | 13.08% | $85.95M |
| Invus financial advisors | 1.01M | 7.98% | $7.12M |
| Nextech invest | 5.29M | 6.92% | $42.66M |
| Sr one capital management, lp | 4.51M | 5.34% | $37.75M |
| Euclidean capital | 989.41K | 4.99% | $11.87M |
| Vr adviser | 6.60M | 4.46% | $79.16M |
| First turn management | 2.16M | 3.89% | $25.91M |
| Ecor1 capital | 6.73M | 3.87% | $80.74M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Ecor1 capital | 6.73M | 3.87% | 5.11M |
| Orbimed advisors | 3.64M | 1.03% | 2.74M |
| Blackrock | 4.83M | 0.00% | 1.65M |
| Goldman sachs group | 1.94M | 0.00% | 1.03M |
| State street | 2.40M | 0.00% | 771.82K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Commodore capital lp | - | - | -2.00M |
| Avidity partners management lp | - | - | -1.27M |
| Frazier life sciences management | - | - | -1.07M |
| Silverarc capital management | 1.12M | 1.27% | -832.20K |
| Jpmorgan chase | 414.79K | 0.00% | -813.74K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Lord, abbett | 564.25K | 0.01% | 564.25K | $4.62M |
| Blue owl capital lp | 515.00K | 0.32% | 515.00K | $4.21M |
| Polar capital | 468.61K | 0.03% | 468.61K | $5.62M |
| Y-intercept (hong kong) | 341.42K | 0.06% | 341.42K | $2.79M |
| Driehaus capital management | 148.78K | 0.01% | 148.78K | $1.79M |
Sold Out
| Holder | Change |
|---|---|
| Capital performance advisors llp | -1.00 |
| Allworth financial lp | -2.00 |
| Larson financial group | -3.00 |
| Clearstead advisors | -4.00 |
| Nelson, van denburg & campbell wealth management group | -8.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 56 | -63.87% | 20,254,766 | -80.98% | 20 | 0.11% | 33 | -63.74% | 16 | -52.94% |
| Sep 30, 2025 | 52 | -62.04% | 16,331,312 | -82.02% | 20 | 0.15% | 33 | -54.17% | 13 | -74.00% |
| Jun 30, 2025 | 143 | -0.69% | 93,335,020 | 17.83% | 119 | 0.96% | 75 | -8.54% | 52 | 36.84% |
| Mar 31, 2025 | 11 | -91.91% | 11,102,130 | -85.35% | 15 | 0.14% | 8 | -89.87% | 2 | -92.86% |
| Dec 31, 2024 | 39 | -68.29% | 10,134,721 | -85.49% | 14 | 0.15% | 26 | -58.06% | 7 | -81.58% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 3.04M | 2.71% | -16.35K |
| Vanguard US Total Market Shares ETF | 1.88M | 2.65% | - |
| Vanguard Total Stock Mkt Idx Inv | 2.45M | 2.19% | - |
| ACAP Strategic A | 2.23M | 1.99% | - |
| Fidelity Growth Compy Commingled Pl O | 1.28M | 1.81% | - |
| iShares Russell 2000 ETF | 1.58M | 1.41% | 1.58M |
| Fidelity Growth Compy Commingled Pl S | 1.32M | 1.18% | 567.00 |
| Biotech Growth Ord | 970.33K | 0.87% | - |
| Eventide Healthcare & Life Sciences I | 951.43K | 0.85% | - |
| T. Rowe Price Health Sciences | 940.15K | 0.84% | -73.80K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Feb 24, 2026 | Piscitelli Dominic | Chief Financial Officer | Sell | $702.69K |
| Jan 16, 2026 | Heyman Richard A. | - | Sell | $38.41K |
| Jan 16, 2026 | Heyman Richard A. | - | Sell | $42.02K |
| Dec 16, 2025 | Multani Pratik S | Chief Medical Officer | Sell | $97.13K |
| Dec 16, 2025 | Piscitelli Dominic | Chief Financial Officer | Sell | $97.13K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | - | 3 |
| 2025 Q4 | - | 6 |
| 2025 Q3 | - | 3 |
| 2025 Q2 | 2 | 9 |
| 2025 Q1 | - | - |
ORIC Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools